Millie
your market intelligence analyst
Search Results
244 results
Your search is now limited to «AstraZeneca» expert search.
pharmaphorum 08/23/2019 04:50
AstraZeneca has bought a priority review voucher (PRV) from Swedish biotech Sobi for $95 million, but isn’t revealing just yet what it intends to use it for.
More from pharmaphorum:
FiercePharmaManufacturing 08/22/2019 10:00
But AstraZeneca has already been preparing for talks with the Chinese government to include roxadustat on the country’s National Reimbursement Drug List.
More from FiercePharmaManufacturing:
ENDPOINTS 08/22/2019 08:47
An emboldened AstraZeneca splurges $95M on a priority review voucher.
More from ENDPOINTS:
BioPharma Dive 08/21/2019 11:30
The trial, called NEPTUNE, paired AstraZeneca's approved checkpoint inhibitor Imfinzi with its experimental drug tremelimumab, testing the two against platinum-based chemo in previously untreated patients.
More from BioPharma Dive:
STAT 08/21/2019 09:33
A combination of AstraZeneca’s (AZN) lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with stage 4 non-small cell lung cancer and high levels of gene mutations, Reuters reports.
More from STAT:
Benzinga 08/21/2019 09:04
What's Next AstraZeneca said it intends to do a deep analysis of the vast clinical and biomarker data from the trial to gain further insights to improve Immuno-oncology approaches for patients with metastatic NSCLC.
More from Benzinga:
Reuters.com 08/21/2019 07:49
AstraZeneca Imfinzi combination fails advanced lung cancer study.
More from Reuters.com:
Pharmafile 08/21/2019 06:10
New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in combination with tremelimumab in the treatment of previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC), compared to standard-of-care (SoC) platinum-based chemotherapy. The study was performed in an all-comers population, with a primary analysis of patients with a high tumour mutational burden (TMB), meaning a higher number of mutations in the tumour’s DNA, potentially making it more visible to the immune system.
More from Pharmafile:
PharmaTimes 08/21/2019 06:08
AstraZeneca has announced that its combination of Imfinzi (durvalumab) and tremelimumab has failed to hit its key target in a late-stage trial assessing its potential in patients with late-stage lung cancer.
More from PharmaTimes:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications